VIVANZA
BIO SCIENCES

November 11, 2017

To,
The Corporate Relationship Department
The Bombay Stock Exchange Limited,
P. J. Towers, Dalal Street, Fort,
Mumbai – 400 001

**Sub: Submission of Unaudited Standalone and Consolidated Financial Results for the Quarter ended 30th September, 2017, during the extended period of 30 days.**
**Ref: Implementation of "IND –AS" for the first time**

Dear Sir/Madam,

This is with reference to the above captioned subject and to inform you that since we are adopting "**IND-AS**" for the first time and as permissible vide SEBI Circular No. CRI/CFD/FAC/62/2016 dated 5th July, 2016, we are opting for submission and publication of Unaudited Standalone and Consolidated Financial Results for the Quarter ended 30th September, 2017, during the extended period of 30 days.

The exact date of Meeting of Board of Directors of the Company for approval of quarter 30th September, 2017 results will be intimated to you in due course.

Kindly take the same on your records.

Thanking you,

Yours faithfully,

**For, Vivanza Biosciences Limited**

Harshul. K. Shah

**Harshul K. Shah**
**Director**
**DIN: 01955747**

VIVANZA BIOSCIENCES LIMITED Ahmedabad